Can "steroid switching" improve steroid-induced musical hallucinations in a patient with terminal cancer?
Identifieur interne : 000828 ( Ncbi/Merge ); précédent : 000827; suivant : 000829Can "steroid switching" improve steroid-induced musical hallucinations in a patient with terminal cancer?
Auteurs : Seitetsu Kanemura [Japon] ; Hitoshi Tanimukai ; Satoru TsunetoSource :
- Journal of palliative medicine ; 2010.
English descriptors
- KwdEn :
- Betamethasone (administration & dosage), Betamethasone (adverse effects), Betamethasone (therapeutic use), Female, Glucocorticoids (administration & dosage), Glucocorticoids (adverse effects), Glucocorticoids (therapeutic use), Hallucinations (chemically induced), Hallucinations (physiopathology), Hallucinations (prevention & control), Humans, Mesothelioma, Middle Aged, Pleural Neoplasms, Prednisolone (administration & dosage), Prednisolone (therapeutic use), Psychoses, Substance-Induced (etiology), Psychoses, Substance-Induced (prevention & control), Steroids (administration & dosage), Steroids (therapeutic use), Terminal Care.
- MESH :
- chemical , administration & dosage : Betamethasone, Glucocorticoids, Prednisolone, Steroids.
- chemical , adverse effects : Betamethasone, Glucocorticoids.
- chemical , therapeutic use : Betamethasone, Glucocorticoids, Prednisolone, Steroids.
- chemically induced : Hallucinations.
- etiology : Psychoses, Substance-Induced.
- physiopathology : Hallucinations.
- prevention & control : Hallucinations, Psychoses, Substance-Induced.
- Female, Humans, Mesothelioma, Middle Aged, Pleural Neoplasms, Terminal Care.
Abstract
The patient was a 57-year-old woman with malignant pleural mesothelioma. She had a past history of anxiety neurosis but not had any history of otological diseases. On admission to our hospice (day 1), she complained of dyspnea and wheezing associated with the progression of her underlying disease. After we started oral betamethasone (2 mg/d), dyspnea was alleviated and the frequency of wheezing was reduced. On day 3, she began to experience musical hallucinations that were manifested in opera/piano concert music and a child's voice. The episodes of musical hallucinations occurred approximately 10 times a day and disappeared spontaneously within several minutes. She had not experienced these symptoms before. We reduced the dose of betamethasone to 1 mg/d, but the musical hallucinations continued. Then on day 11, we switched betamethasone (1 mg/d) to prednisolone (10 mg/d) and we then gradually tapered off prednisolone. The frequency of musical hallucinations decreased and she ceased to experience musical hallucinations on day 29. However, on day 40, her dyspnea was aggravated again, so we started treatment with prednisolone (5 mg/d). Dyspnea was alleviated and no musical hallucinations occurred. On Day 51, dyspnea was worsened and we switched prednisolone to betamethasone (4 mg/d), which she hoped to use. The betamethasone alleviated the dyspnea but she developed musical hallucinations that were similar to the previous episodes. The musical hallucinations disappeared spontaneously 4-5 days later without changing the betamethasone. Musical hallucinations never occurred thereafter. She later died due to the exacerbation of disease.
DOI: 10.1089/jpm.2010.9751
PubMed: 21155649
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000338
- to stream PubMed, to step Curation: 000338
- to stream PubMed, to step Checkpoint: 000353
Links to Exploration step
pubmed:21155649Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Can "steroid switching" improve steroid-induced musical hallucinations in a patient with terminal cancer?</title>
<author><name sortKey="Kanemura, Seitetsu" sort="Kanemura, Seitetsu" uniqKey="Kanemura S" first="Seitetsu" last="Kanemura">Seitetsu Kanemura</name>
<affiliation wicri:level="1"><nlm:affiliation>Hospice, Gratia Hospital, Mino, Osaka 562-8567, Japan. k.seitetsu@gmail.com</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Hospice, Gratia Hospital, Mino, Osaka 562-8567</wicri:regionArea>
<wicri:noRegion>Osaka 562-8567</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tanimukai, Hitoshi" sort="Tanimukai, Hitoshi" uniqKey="Tanimukai H" first="Hitoshi" last="Tanimukai">Hitoshi Tanimukai</name>
</author>
<author><name sortKey="Tsuneto, Satoru" sort="Tsuneto, Satoru" uniqKey="Tsuneto S" first="Satoru" last="Tsuneto">Satoru Tsuneto</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="doi">10.1089/jpm.2010.9751</idno>
<idno type="RBID">pubmed:21155649</idno>
<idno type="pmid">21155649</idno>
<idno type="wicri:Area/PubMed/Corpus">000338</idno>
<idno type="wicri:Area/PubMed/Curation">000338</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000353</idno>
<idno type="wicri:Area/Ncbi/Merge">000828</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Can "steroid switching" improve steroid-induced musical hallucinations in a patient with terminal cancer?</title>
<author><name sortKey="Kanemura, Seitetsu" sort="Kanemura, Seitetsu" uniqKey="Kanemura S" first="Seitetsu" last="Kanemura">Seitetsu Kanemura</name>
<affiliation wicri:level="1"><nlm:affiliation>Hospice, Gratia Hospital, Mino, Osaka 562-8567, Japan. k.seitetsu@gmail.com</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Hospice, Gratia Hospital, Mino, Osaka 562-8567</wicri:regionArea>
<wicri:noRegion>Osaka 562-8567</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tanimukai, Hitoshi" sort="Tanimukai, Hitoshi" uniqKey="Tanimukai H" first="Hitoshi" last="Tanimukai">Hitoshi Tanimukai</name>
</author>
<author><name sortKey="Tsuneto, Satoru" sort="Tsuneto, Satoru" uniqKey="Tsuneto S" first="Satoru" last="Tsuneto">Satoru Tsuneto</name>
</author>
</analytic>
<series><title level="j">Journal of palliative medicine</title>
<idno type="e-ISSN">1557-7740</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betamethasone (administration & dosage)</term>
<term>Betamethasone (adverse effects)</term>
<term>Betamethasone (therapeutic use)</term>
<term>Female</term>
<term>Glucocorticoids (administration & dosage)</term>
<term>Glucocorticoids (adverse effects)</term>
<term>Glucocorticoids (therapeutic use)</term>
<term>Hallucinations (chemically induced)</term>
<term>Hallucinations (physiopathology)</term>
<term>Hallucinations (prevention & control)</term>
<term>Humans</term>
<term>Mesothelioma</term>
<term>Middle Aged</term>
<term>Pleural Neoplasms</term>
<term>Prednisolone (administration & dosage)</term>
<term>Prednisolone (therapeutic use)</term>
<term>Psychoses, Substance-Induced (etiology)</term>
<term>Psychoses, Substance-Induced (prevention & control)</term>
<term>Steroids (administration & dosage)</term>
<term>Steroids (therapeutic use)</term>
<term>Terminal Care</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Betamethasone</term>
<term>Glucocorticoids</term>
<term>Prednisolone</term>
<term>Steroids</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Betamethasone</term>
<term>Glucocorticoids</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Betamethasone</term>
<term>Glucocorticoids</term>
<term>Prednisolone</term>
<term>Steroids</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hallucinations</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychoses, Substance-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hallucinations</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Hallucinations</term>
<term>Psychoses, Substance-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Mesothelioma</term>
<term>Middle Aged</term>
<term>Pleural Neoplasms</term>
<term>Terminal Care</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The patient was a 57-year-old woman with malignant pleural mesothelioma. She had a past history of anxiety neurosis but not had any history of otological diseases. On admission to our hospice (day 1), she complained of dyspnea and wheezing associated with the progression of her underlying disease. After we started oral betamethasone (2 mg/d), dyspnea was alleviated and the frequency of wheezing was reduced. On day 3, she began to experience musical hallucinations that were manifested in opera/piano concert music and a child's voice. The episodes of musical hallucinations occurred approximately 10 times a day and disappeared spontaneously within several minutes. She had not experienced these symptoms before. We reduced the dose of betamethasone to 1 mg/d, but the musical hallucinations continued. Then on day 11, we switched betamethasone (1 mg/d) to prednisolone (10 mg/d) and we then gradually tapered off prednisolone. The frequency of musical hallucinations decreased and she ceased to experience musical hallucinations on day 29. However, on day 40, her dyspnea was aggravated again, so we started treatment with prednisolone (5 mg/d). Dyspnea was alleviated and no musical hallucinations occurred. On Day 51, dyspnea was worsened and we switched prednisolone to betamethasone (4 mg/d), which she hoped to use. The betamethasone alleviated the dyspnea but she developed musical hallucinations that were similar to the previous episodes. The musical hallucinations disappeared spontaneously 4-5 days later without changing the betamethasone. Musical hallucinations never occurred thereafter. She later died due to the exacerbation of disease.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21155649</PMID>
<DateCreated><Year>2010</Year>
<Month>12</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted><Year>2011</Year>
<Month>04</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-7740</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>13</Volume>
<Issue>12</Issue>
<PubDate><Year>2010</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Journal of palliative medicine</Title>
<ISOAbbreviation>J Palliat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Can "steroid switching" improve steroid-induced musical hallucinations in a patient with terminal cancer?</ArticleTitle>
<Pagination><MedlinePgn>1495-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1089/jpm.2010.9751</ELocationID>
<Abstract><AbstractText>The patient was a 57-year-old woman with malignant pleural mesothelioma. She had a past history of anxiety neurosis but not had any history of otological diseases. On admission to our hospice (day 1), she complained of dyspnea and wheezing associated with the progression of her underlying disease. After we started oral betamethasone (2 mg/d), dyspnea was alleviated and the frequency of wheezing was reduced. On day 3, she began to experience musical hallucinations that were manifested in opera/piano concert music and a child's voice. The episodes of musical hallucinations occurred approximately 10 times a day and disappeared spontaneously within several minutes. She had not experienced these symptoms before. We reduced the dose of betamethasone to 1 mg/d, but the musical hallucinations continued. Then on day 11, we switched betamethasone (1 mg/d) to prednisolone (10 mg/d) and we then gradually tapered off prednisolone. The frequency of musical hallucinations decreased and she ceased to experience musical hallucinations on day 29. However, on day 40, her dyspnea was aggravated again, so we started treatment with prednisolone (5 mg/d). Dyspnea was alleviated and no musical hallucinations occurred. On Day 51, dyspnea was worsened and we switched prednisolone to betamethasone (4 mg/d), which she hoped to use. The betamethasone alleviated the dyspnea but she developed musical hallucinations that were similar to the previous episodes. The musical hallucinations disappeared spontaneously 4-5 days later without changing the betamethasone. Musical hallucinations never occurred thereafter. She later died due to the exacerbation of disease.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kanemura</LastName>
<ForeName>Seitetsu</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Hospice, Gratia Hospital, Mino, Osaka 562-8567, Japan. k.seitetsu@gmail.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tanimukai</LastName>
<ForeName>Hitoshi</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tsuneto</LastName>
<ForeName>Satoru</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Palliat Med</MedlineTA>
<NlmUniqueID>9808462</NlmUniqueID>
<ISSNLinking>1557-7740</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013256">Steroids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9842X06Q6M</RegistryNumber>
<NameOfSubstance UI="D001623">Betamethasone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber>
<NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001623">Betamethasone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005938">Glucocorticoids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006212">Hallucinations</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008654">Mesothelioma</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D010997">Pleural Neoplasms</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011239">Prednisolone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011605">Psychoses, Substance-Induced</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D013256">Steroids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D013727">Terminal Care</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>12</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>12</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>4</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1089/jpm.2010.9751</ArticleId>
<ArticleId IdType="pubmed">21155649</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Japon</li>
</country>
</list>
<tree><noCountry><name sortKey="Tanimukai, Hitoshi" sort="Tanimukai, Hitoshi" uniqKey="Tanimukai H" first="Hitoshi" last="Tanimukai">Hitoshi Tanimukai</name>
<name sortKey="Tsuneto, Satoru" sort="Tsuneto, Satoru" uniqKey="Tsuneto S" first="Satoru" last="Tsuneto">Satoru Tsuneto</name>
</noCountry>
<country name="Japon"><noRegion><name sortKey="Kanemura, Seitetsu" sort="Kanemura, Seitetsu" uniqKey="Kanemura S" first="Seitetsu" last="Kanemura">Seitetsu Kanemura</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000828 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000828 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Musique |area= OperaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:21155649 |texte= Can "steroid switching" improve steroid-induced musical hallucinations in a patient with terminal cancer? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:21155649" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a OperaV1
This area was generated with Dilib version V0.6.21. |